Compare Mesoblast Limited (MESO) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VanEck Vietnam ETF — how do they compare? Mesoblast Limited trades at $16.34 (market cap $2.17B), while VanEck Vietnam ETF trades at $16.92. Which is the better fit depends on your goals.
| MESO | VNM | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $19.80 |
52-Week Low | $12.88 | $15.35 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VNM trades at $16.84, down 2.88% on the day, reflecting bearish technical signals with moving averages indicating a downtrend. The stock lacks disclosed valuation ratios, and recent news highlights underperformance relative to other emerging markets. Key support and resistance are tightly clustered around $17, suggesting a critical price zone.
The outlook remains cautious due to technical weakness and emerging market headwinds. Investment opportunities hinge on Vietnam's economic reclassification potential, but risks include power grid strains and geopolitical tensions. Analyst sentiment is mixed, with oscillators showing some bullish divergence amid broader bearish indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
